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ABSTRACT: Cocrystals of biologically active molecular compounds have
potential utility in drug products thanks to their effect upon physicochemical
properties such as aqueous solubility. The fact that control of
cocrystallization can be more challenging than crystallization of single-
component crystals means that systematic studies that address the
methodology of cocrystal screening, production, and purification are a
topical subject. We previously reported a comparison of slow evaporation vs
mechanochemistry for a library of 25 molecular cocrystals. Herein, we
compare the previously reported mechanochemistry results (solvent-drop
grinding (SDG) with eight solvents) with new results obtained from
slurrying in five preferred solvents using the same library of 25 cocrystals.
Overall, both methods were found to be effective with slurrying and SDG being 94 and 78.5% successful, respectively. Importantly,
96% of the cocrystals formed via slurrying were observed to be free of starting materials (coformers) according to powder X-ray
diffraction (PXRD), whereas this was the case for only 72% of the cocrystals prepared by SDG. Slurrying therefore compared
favorably with mechanochemistry, which tends to leave small amounts of unreacted coformer(s) as byproducts, and solution
crystallization, which often affords crystals of the least soluble coformer because it can be difficult to control the saturation of three
or more solids. Perhaps the most interesting and surprising result of this study was that water slurrying proved to be highly effective,
even for low-solubility coformers. Indeed, water slurrying was found to be effective for 21 of the 25 cocrystals studied.
■ INTRODUCTION
Cocrystals have been defined as “solid single-phase crystalline
materials made up of two or more different ionic and/or
molecular components, generally in a stoichiometric ratio that
are neither solvates, nor simple salts”.1 Crystal engineering of
cocrystals has grown as a research subject over the last two
decades thanks in part to the inherent amenability of most
biological molecules to form pharmaceutical cocrystals through
hydrogen-bonded interactions2−8 and the tendency of the
resulting cocrystals to alter the physicochemical properties of a
molecular compound without affecting its molecular struc-
ture.6,8 Cocrystals have thereby become relevant to the
pharmaceutical industry as they can enhance the bioavailability
of low-solubility molecular compounds,9 sometimes dramati-
cally.10 A pharmaceutical cocrystal is composed of an active
pharmaceutical ingredient (API) and at least one pharmaceuti-
cally acceptable coformer.2 To the best of our knowledge, at
least eight pharmaceutical cocrystals have thus far been
approved by regulatory bodies and marketed as drug
products.11 In general, the potential utility of pharmaceutical
cocrystals tends to be related to the Biopharmaceutics
Classification System (BCS)12 class of the API in question.
Specifically, Class II and IV APIs, those drug substances that
exhibit low aqueous solubility, are particularly suitable
candidates for cocrystallization studies. The utility of cocrystals
is not limited to pharmaceuticals. They have also been studied
in the context of nonlinear optical materials,13 molecular
semiconductors,14 as a medium for stereocontrolled syn-
thesis,15 and to enhance the performance of energetic materials
(explosives, propellants, and pyrotechnics).16
Interest in cocrystals results in part from their amenability to
crystal engineering studies through the exploitation of
supramolecular synthons, typically based upon complementary
hydrogen bonding. The concept of supramolecular synthons
was introduced by Desiraju in 1995,17 and the relevance of
supramolecular heterosynthons, supramolecular synthons
between different but complementary functional groups,2 to
pharmaceutical cocrystal design using crystal engineering was
recognized by several groups in 20035−7 and 2004.8 Several
studies have revealed that the hierarchy of supramolecular
synthons is key to the design of cocrystals from first
principles.18−21 Most relevant to the study herein are cocrystals
containing phenol or carboxylic acid coformers and their
tendency to form supramolecular heterosynthons with pyridyl
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moieties through OH···Naromatic and COOH···Naromatic inter-
actions, respectively22,23 (Scheme 1, IV and V). Importantly,
carboxylic acid moieties, phenolic groups, and pyridyl rings are
widely encountered in APIs7,24,25 and FDA-approved co-
formers.21 These studies collectively emphasize the robust
nature of these supramolecular heterosynthons and is a reason
why we selected cocrystals based upon COOH···Naromatic and
OH···Naromatic interactions for study.
Crystal engineering approaches to the design of certain
families of cocrystals have reached a level of maturity thanks, at
least in part, to the understanding gained from the hierarchy
studies discussed above. This is not generally the case,
however, for the methods used to discover and prepare
cocrystals, where systematic studies that compare various
approaches are quite few.26 With respect to discovery
(screening) and preparation of cocrystals, mechanochemical
grinding, solution evaporation, and slurrying are the most
widely reported methods as discussed below.
Solid-state methods are used at the industrial scale, mainly
with respect to inorganic solids and materials27,28 or to
produce amorphous phases.29 Mechanochemistry refers to
inducing reactivity in the solid state via input of mechanical
energy. Its efficiency results from typically fast reaction times,
generally high yields of product and little waste since only
minimal amounts of solvent are needed during the grinding
process.30,31 In recent years, mechanochemistry has evolved to
include continuous processes such as twin-screw extrusion
(TSE) (grinding of samples between two countering-rotating
screwing elements)32 and hot-melt extrusion33 (melting of
reactants). Supercritical fluid methods34 using supercritical
CO2 as a solvent
35 or antisolvent36 have also been studied and
can eliminate the need for liquid solvent(s) altogether. With
respect to the discovery and preparation of cocrystals, which
typically occur at the milligram scale using either a pestle and
mortar or ball mill, grinding has become a favored method.37,38
Multiple terms have been coined for this approach, including
solvent-drop grinding39,40 (SDG), liquid-assisting grinding
(LAG),37 or kneading.41,42 We adopt the term SDG herein.
We note that, although SDG has wide acceptance with respect
to cocrystal screening and preparation, grinding can result in
crystalline defects that might generate partial amorphous
content or incomplete conversion. In such situations, addi-
tional purification step(s) would be required.43
A slurry is a mixture of solid particles suspended in a liquid.
Slurries can be used for bulk transportation of solids such as
soil,44 but they are also used in a range of disciplines45,46
including for cocrystals.47 Using slurries is relatively non-labor-
intensive and its variables can be optimized to afford high-
purity products. The slurry technique also has advantages in
the context of pharmaceutical materials since it typically results
in thermodynamically stable products. For example, slurrying
has been used to prepare the most stable cocrystal form48
under a given set of conditions and for the identification of
thermodynamically stable polymorphs.49 Slurrying has been
utilized for cocrystal screening47,50 and for scale-up of
cocrystals for dissolution or solubility studies.6,51 Slurrying
can also be used for solution-mediated phase transforma-
tions;52 Zhang’s group used slurries to prepare caffeine
cocrystals,53 including one between caffeine and adipic
acid,54 which could not be isolated by SDG according to a
study from the Jones group.55 Zhang’s group also reported that
cocrystal formation can be related to hydrate and solvate
formation by molecular compounds based upon a thermody-
namic understanding of their physical stability.52 We take a
similar approach herein by selecting the parameters for our
slurry experiments using solubility data from the pure
coformers. Despite the larger consumption of solvent and
longer reaction times compared to SDG, the use of greener or
more “economically friendly” solvents such as water can
overcome environmental concerns and some of the costs
associated with solvent waste as discussed below.
Solution crystallization continues to be widely used to
discover and prepare cocrystals.18−21 This technique involves
controlled nucleation and growth of a cocrystal from a solution
of its coformers under supersaturated conditions, typically
induced by slow evaporation of solvent. The isolation of single
crystals means that structural characterization by single-crystal
X-ray diffraction (SCXRD) is a desirable outcome, although
powder X-ray diffraction (PXRD) has been shown to be
effective for the determination of cocrystal structures.56
Nevertheless, isolation of cocrystals from solution can be
more challenging than for single-component crystals. Ternary
phase diagrams can be generated to determine the conditions,
typically a narrow range of conditions, under which cocrystals
will be favored over low-solubility coformers.26,57 The relative
amount of solvent and the relative solubility of the coformers
in the specified solvent can be a decisive factor.58 For larger-
scale production, slow evaporation can be time-consuming and
produce large amounts of solvent waste. In general, the use of
solvents is negative in terms of environmental impact but can
be essential for the specifications needed for industrial
production, e.g., for formulation and purification.59 A high
rate of solvent consumption can lead to costly waste
management and regimented safety procedures due to
increased health risks. This poses the question of “what is a
green solvent?” In 2007, Fischer60 attempted to address this
question from two aspects: (i) environmental, health, and
safety and (ii) energy demand. Slater and Savelski61 considered
12 environmental factors including the occupational hazard of
a worker and their environment. Initiatives have been
implemented since the mid-20th century to avoid the use of
carcinogenic or ozone-depleting solvents, including the
replacement of benzene with toluene in 197162,63 and the
ban of carbon tetrachloride in 1989.64
Scheme 1. Supramolecular Homosynthons (I, II, and III)
and Supramolecular Heterosynthons (IV and V) That Are
Present in the Cocrystals of This Study
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Herein, we systematically address the utility of slurrying vs
mechanochemistry for cocrystal preparation as a continuation
of our previous study that compared solution crystallization
and mechanochemistry with a library of 25 known cocrystals
(Schemes 2−5).65 In addition to model compound coformers,
carbamazepine (CBZ) was included in our previous study as
CBZ is an example of a BCS Class II66 drug substance. CBZ is
the API in the anticonvulsant drug product Tegretol.67 Herein,
we use the same library of 25 cocrystals and therefore rely
upon the SDG data reported previously. The solvents selected
for our slurry experiments were water, methanol (MeOH),
acetonitrile (MeCN), ethyl acetate (EtOAc), and 2-butanone,
also commonly known as methyl ethyl ketone (MEK). These
solvents offer different functionalities and different levels of
polarity, i.e., aqueous/organic, alcohol/ketone, and protic/
aprotic. Nonpolar and halogenated solvents were not
considered for this study due to their increased health risks.
This solvent choice was also guided by the green solvent
selection guide for chemists by Clark et al.68 This guide noted
that GSK and Pfizer have categorized MeCN as useable but
problematic. However, it is one of Sanofi’s recommended
solvents due to low cost and its common use in organic
synthesis and purification, was therefore chosen for this study.
■ EXPERIMENTAL SECTION
Reagents and solvents were obtained from Sigma-Aldrich (glutaric
acid, isophthalic acid, trimesic acid, hydroquinone, benzoquinone, 4-
aminobenzoic acid, oxalic acid, 1-naphthol, terephthaldehyde,
saccharin, nicotinamide, resorcinol, and 2,6-pyridinecarboxylic acid)
and TCI (benzoic acid, trans-1,2-bis-(4-pyridyl)ethylene, 4,4′-
bipyridine, 1,2-bis-(4-pyridyl)ethane, 4,4′-biphenol, tetramethylpyr-
azine, naproxen, carbamazepine, aspirin, and 2,7-dihydroxynaphtha-
lene) and used as received. X-ray powder diffraction (PXRD) was
used for phase identification of coformers and cocrystals. We note
that peak positions in experimental PXRD patterns can exhibit slight
shifting compared to calculated PXRD patterns obtained from
SCXRD data because of thermal expansion if data were collected at
different temperatures.
Powder X-ray Diffraction (PXRD). PXRD studies of micro-
crystalline samples were performed in Bragg−Brentano geometry on a
Panalytical Empyrean diffractometer (40 kV, 40 mA, Cu Kα1,2 (λ =
1.5418 Å)). A scan speed of 0.5 s/step (6°/min) with a step size of
0.05° in 2θ was used at ambient temperature.
Solubility Test Using Gravimetric Method. A slurry containing
each coformer was stirred for 24 h in 2 mL of deionized water,
MeOH, MeCN, EtOAc, or MEK. The resulting slurry was filtered
using Whatmann 0.45 μm poly(tetrafluoroethylene) (PTFE) syringe
filters into a preweighed vial. The vial was reweighed and left in an
oven at 40 °C until evaporation was complete. The vial was reweighed
after drying.
Slurry Experiments. Each slurry used 0.5 mL of solvent in a 10.5
mL vial with a diameter of 16 mm. A 10 mm stirring bar was placed
into each vial and set to stir at 150 rpm for 24−48 h. The slurry was
then filtered, washed with the solvent used for that slurry, and air-
dried before being analyzed by PXRD. The relative amounts of
coformer used for each slurry were based upon the stoichiometric
ratio of the target cocrystal. The total amount of coformers used for
each slurry was based on the solubility of each coformer to ensure that
both coformers would be saturated under the conditions of the
slurrying experiment. If the slurry experiment was subsequently
deemed to be unsuccessful at ambient temperature, it was repeated at
30 °C. More details about the slurry experiments are presented in the
Supporting Information.
Mechanochemical Methods (as Previously Reported). Co-
formers were subjected to grinding with an agate mortar and pestle for
4 min and thereafter characterized by infrared (IR) and PXRD
experiments. In the event that partial conversion was achieved, a
SPEX 8000 M Mixer/Mill was used for two stages of 10 min with the
addition of a solvent prior to each stage. The stoichiometric ratios that
the cocrystals exhibited from solution crystallization were used for
grinding unless otherwise specified. Solvents used per 100 mg of
cocrystal formers during SDG were as follows: MeOH 20 μL; EtOAc
20 μL; dimethylsulfoxide (DMSO) 4 μL; water 5 μL; toluene (Tol)
20 μL; cyclohexane (Cyclohex) 20 μL; chloroform 20 μL;
dimethylformamide (DMF) 4 μL.
Scheme 2. Pyridyl Coformers Present in Cocrystals 1−18
Scheme 3. Carboxylic Acid Coformers Present in Cocrystals
1−9
Scheme 4. Phenolic Coformers Present in Cocrystals 10−17
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■ RESULTS AND DISCUSSION
Design of Slurry Experiments. There are multiple
variables associated with a slurry experiment that involves
coformers. Two approaches were taken herein. Initially, an
excess of the more soluble coformer used in each slurry was
used, but this tended to result in isolation of the less soluble
coformer as determined by PXRD. These preliminary results
prompted us to take a different approach in which both
coformers were saturated during the slurry experiment.
Saturation was ensured by using the measured solubility of
the more soluble coformer (Table 1) and adding an additional
10 mg of coformer. The appropriate stoichiometric amount of
the second coformer was then determined and used. In
essence, this approach follows that proposed by Zhang and co-
workers52 by promoting nucleation of the cocrystal since;
when both coformers are supersaturated, it is more likely that
the system is in the appropriate region of ternary phase
diagram to favor cocrystallization. This approach may be
necessary for coformers that have a more stable hydrated phase
compared to their cocrystal(s), e.g., CBZ dihydrate in the
context of the CBZ cocrystals. The protocol might be further
modified for scale-up, but for the purpose of the study herein,
this approach was used without further modification.
Solubility Data. Solubility data was obtained for each
coformer as presented in Table 1 and reveal that there is a
broad range of solubility, both absolutely and relatively. For
example, nicotinamide, glutaric acid, and resorcinol exhibit
high aqueous solubilities (419.1, 570.0, and 566.5 mg/mL
respectively), whereas 4, 4′-bipyridine and derivatives have an
aqueous solubility of 1.6 mg/mL or less (cocrystals 5 and 6).
Notably, this is representative of many pharmaceutical
cocrystals, which are typically composed of an API with a
low aqueous solubility and a high-solubility coformer.6,8
Cocrystals Containing the COOH···Naromatic Supramolec-
ular Heterosynthon (1−9). The results obtained from
carboxylic acid and pyridyl coformers are presented in Table
2 and are color-coded according to the outcome. As revealed
by Table 2, cocrystals 1−8 were formed via SDG and slurry for
all solvents used as determined by a comparison of
experimental and calculated PXRD data (Figures S1−S8).
However, in most SDG experiments, it was observed that,
although the experimental PXRD pattern matched that of the
calculated PXRD pattern of the target cocrystal, there were
additional peaks corresponding to pure coformers. In such
situations, additional milling was conducted to promote
complete conversion from coformers to cocrystal. With respect
to SDG, inefficient mixing caused by clumping of particles of
the coformers could be the reason for incomplete conversion
to cocrystal. Cocrystal 9, the cocrystal of trimesic acid and
Scheme 5. CBZ and Coformers in Cocrystals 18−25
Table 1. Solubility Data for Each Coformer in Water,










benzoic acid <1.0 306.4 81.5 175.0
trans-1,2-bis(4-pyridyl)
ethylene
<1.0 289.0 <1.0 <1.0
4,4′-bipyridine 1.8 456.7 84.1 134.6
glutaric acid 570.0 458.0 99.5 602.2
1,2-bis(4-pyridyl)
ethane
<1.0 426.6 115.7 67.1
4,4′-biphenol <1.0 57.1 13.3 56.1
tetramethylpyrazine <1.0 <1.0 <1.0 <1.0
isophthalic acid <1.0 10.8 2.0 3.4
trimesic acid <1.0 <1.0 <1.0 1.8
hydroquinone 72.9 269.6 100.8 165.1
naproxen <1.0 53.6 36.7 50.5
benzoquinone 1.8 4.8 15.2 57.7
carbamazepine <1.0 63.4 43.5 12.7
4-aminobenzoic acid 2.7 146.9 57.9 75.5
oxalic acid 85.3 190.3 110.6 96.8
aspirin 2.0 221.8 63.3 25.4
1-naphthol 2.7 197.0 71.3 61.2
terephthalaldehyde <1.0 221.5 76.2 79.7
saccharin 2.9 36.4 28.2 30.2
nicotinamide 419.1 180.2 21.2 10.8
2,7-
dihydroxynaphthalene
4.5 379 76.2 79.7
resorcinol 566.5 544.4 525.8 443.5
2,6-pyridinecarboxylic
acid
4.0 22.9 <1.0 <1.0
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trans-1,2-bis(4-pyridyl)ethylene, only formed in DMSO and
DMF through SDG. An unknown phase resulted from SDG
using toluene, whereas physical mixtures of coformers were
isolated from SDG involving water, MeOH, or EtOAc.
Table 2. Comparison of the Results of Slurry and SDG65 Experiments for Cocrystals 1−9a
aRed = physical mixture of pure coformers, green = cocrystal formed, yellow = unidentified form. *Indicates the presence of pure coformers as
measured by PXRD (see the SI for details).
Table 3. Comparison of the Results of Slurry and SDG65 Experiments for Cocrystals 10−17a
aRed = physical mixture of pure coformers, green = cocrystal formed, yellow = unidentified form, *Indicates the presence of pure coformers as
measured by PXRD (see the SI for details).
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Interestingly, the slurrying experiments afforded cocrystal 9
with all five solvents used, three of which were solvents that
were used unsuccessfully for the SDG experiments (Figure S9).
We note that even coformers with an aqueous solubility of <1
mg/mL formed via slurry in water, e.g., cocrystal 4. Such a
situation is favorable, as one would expect a high overall yield
as relatively low quantities of coformers remain in solution
(assuming the cocrystal does not exhibit a substantial increase
in solubility compared to the parent coformers). Overall, the
results presented in Table 2 suggest that slurrying might be
better suited to produce high-purity products than SDG.
Cocrystals Containing the OH···Narom Supramolecular
Heterosynthon (10−17). The results obtained from phenol
and pyridyl coformers are presented in Table 3 and are color-
coded according to the outcome. Cocrystals 10−13 were
isolated from all solvents tested via SDG and slurry (Figures
S10−S12). However, 10 of the SDG experiments (40% of the
experiments conducted) contained additional PXRD peaks
corresponding to pure coformers as following analysis of
calculated PXRD patterns. Conversely, only 5% of the slurry
experiments exhibited additional PXRD peaks. Cocrystal 13,
the 1:1 cocrystal of 4,4′-phenol and trans-1,2-bis(4-pyridyl)-
ethylene, exhibited an additional peak in its water slurry PXRD
pattern at approximately 23°, which correlates to a peak from
4,4′-biphenol (Figure S13). Cocrystal 14 formed in all slurry
solvents (Figure S14). With respect to the SDG method,
cocrystal 14 formed in the same solvents used for slurry (H2O,
MeOH, and EtOAc), DMF, and DMSO. Cocrystal 14 did not
form, however, from SDG in CHCl3, Tol, or Cycloh.
Interestingly, in attempts to prepare cocrystal 15 of hydro-
quinone and tetramethylpyrazine via SDG, the three solvents
that did not produce 14 produced an unknown phase with
PXRD peaks that neither matched the targeted cocrystals nor
the pure coformers. This phase has not been structurally
characterized and is likely to be a polymorph (of the cocrystal
or of the pure coformers), a different stoichiometry cocrystal
or a solvate/hydrate of a cocrystal. Cocrystal 15 was afforded
from the remaining SDG solvents, and all of the slurry solvents
although PXRD peaks corresponding to coformer were
observed when water was used as a solvent for SDG (Figure
S15). With the exception of water for the slurry method,
cocrystal 16 formed in all solvents used for both SDG and
slurry. An unknown phase was obtained from the water slurry
of resorcinol and tetramethylpyrazine, its PXRD pattern being
different from polymorphs or hydrates of the cocrystal or the
individual coformers archived in the Cambridge Structural
Database (CSD; version 5.42, February 2021) (Figure S16).
An issue with the slurry experiments of cocrystal 15 was that
the solubility of resorcinol in all selected solvents is greater
than 500 mg/mL, therefore requiring a large amount of
coformer and additional solvent to achieve efficient mixing.
This would be problematic for scale-up using slurry thus SDG
would likely be preferred over slurry for this cocrystal.
Cocrystal 17 neither formed by SDG nor slurry in water,
instead resulting in an unknown phase similar to cocrystal 16.
Once again, the PXRD pattern of the solids isolated did not
match any of the relevant solid forms archived in the CSD.
Nevertheless, 17 was successfully isolated in the other selected
solvents (Figure S17).
Cocrystals Containing Carbamazepine, CBZ (18−25).
CBZ is a BCS class II API that was one of the first APIs
studied in the context of systematic cocrystallization studies.69
CBZ has been widely studied since, partly as a result of its
promiscuity in terms of crystal forms; a CSD survey (version
5.42, February 2021) revealed that 148 structures containing
CBZ are archived in the CSD, including more than 61
cocrystals, 17 solvates, and 5 polymorphs. The results obtained
for CBZ cocrystals are presented in Table 4 and are color-
coded according to the outcome. Cocrystal 18, a 2:1 cocrystal
between CBZ and 4,4′-bipyridine, formed in all SDG
experiments including that with water. When the slurry
method was applied in water, however, the resulting PXRD
pattern (Figure S18) indicates that dihydrate form of CBZ
(REFCODE/FEFNOT01) had been isolated. A 1:1 stoichi-
ometry was targeted for cocrystal 19 between 4-aminobenzoic
acid (4AB)/CBZ. Rather, a 2:1 cocrystal was afforded, with
water and EtOAc generating the hydrated form of the 2:1
cocrystal (Figure S19). Rodriǵuez-Hornedo’s and co-workers70
investigated the stability of these cocrystals and concluded that
the 1:1 cocrystal is more stable at higher 4AB concentrations,
whereas the 2:1 cocrystal is favored at lower 4AB
concentrations. As the relative solubilities of CBZ and 4AB
Table 4. Comparison of the Results of Slurry and SDG65 Experiments for Carbamazepine (CBZ) Cocrystals 18−25a
aRed = physical mixture of pure coformers, green = cocrystal formed, blue = different-stoichiometry cocrystal than that targeted. *Indicates the
presence of pure coformers as measured by PXRD (see the SI for details).
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are similar in all slurry solvents used, their work supports our
isolation of the 2:1 cocrystals. Conversely, the expected 1:1
stoichiometry cocrystal was obtained via SDG using MeOH
and EtOAc, with the hydrated 1:1 cocrystal being isolated from
water and DMSO. The remaining solvents afforded a physical
mixture of the two coformers. Cocrystal 20 was afforded in all
five slurry solvents but did not form when the same solvents
were used in SDG with the exception of water (Figure S20).
The 2:1 cocrystal of benzoquinone and CBZ, cocrystal 21, was
afforded when coformers were ground in the presence of
MeOH, DMSO, and DMF or slurried in water, MeOH,
MeCN, EtOAc, or MEK (REFCODE/UNEYOB). Excess
CBZ was identified in the PXRD pattern obtained after water
slurry, whereas physical mixtures were produced in the
remaining SDG experiments (Figure S21). Cocrystal 22 did
not form by water slurry but was afforded via SDG in the
presence of water. Cocrystal 22 resulted from the remaining
slurry solvents, with CBZ present in the PXRD patterns of the
solids isolated from MeOH, MeCN, and MEK (Figure S22).
CBZ cocrystals 23 and 24, containing saccharin and
nicotinamide, respectively, were isolated from slurry and
SDG in the same solvents with the exception of water for
cocrystal 23 (Figures S23 and S24). The 1:1 cocrystal between
CBZ and aspirin only formed in DMSO using SDG but formed
readily from slurrying in water, MeOH, EtOAc, and MEK. The
anhydrous form of CBZ is the product of the MeCN slurry.
Analysis of Results. It is well recognized that cocrystals can
afford drug substances with improved physicochemical proper-
ties, but it is unclear which methodology is most suitable for
screening and production of cocrystals. The study herein
compares the three most commonly used methodologies, slow
evaporation, mechanochemistry, and slurry, with respect to
their ability to produce cocrystals. In our earlier study, we
compared slow evaporation from solution with mechanochem-
istry.65 We therein indicated that, although solution crystal-
lization has the advantage of generating suitable crystals for
SCXRD analysis, there are pitfalls. In particular, outcomes are
heavily impacted by the relative solubility of the coformers and
the ternary phase diagram can change dramatically from one
solvent to another. The effect of solvent means that many
attempts to optimize a solvent system may be required, making
the process of determining the optimal crystallization
conditions time-consuming. In essence, isolation of a specific
cocrystal through solution crystallization is more challenging
than isolation of single-component crystals because the regions
of the ternary phase diagram that thermodynamically favor a
specific cocrystal can be quite narrow.26,57,58 In addition, when
scaling up solution crystallization processes, large amounts of
solvent waste are expected to be produced.
Interest in the use of mechanochemical methods for the
discovery and synthesis of materials has grown as they can offer
fast reaction times, high yield, and use little or no solvent,
meaning low waste and high atom economy.30 In terms of
screening, mechanochemistry can take just minutes and is
therefore faster than other methods. SDG can also be
advantageous since it is largely unaffected by the relative
solubility of the individual coformers. This is evident for
cocrystals that are composed of highly soluble coformers. For
example, resorcinol (cocrystal 23) has a solubility of >500 mg/
mL in all of the slurry solvents and SDG proved to be the most
suitable method for this particular cocrystal. Overall, we
observed a 78.5% success rate for preparing cocrystals by SDG,
although over a quarter (28%) of the solids produced physical
mixtures of coformers and cocrystals. As a consequence,
additional purification step(s) may be required, such as
recrystallization. The degree of scale-up of cocrystals by
mechanochemistry might also be problematic as ball milling is
a batch process that is prone to clumping of solids and
heterogeneous outcomes. The development of twin-screw
extrusion (TSE) mills offers the possibility of a continuous
process for synthesizing cocrystals and other classes of
materials, but there are some drawbacks to TSE.71
The slurry method proved to be most successful as several
cocrystals that were not afforded by SDG were formed via
slurry in the same set of solvents. Further, the slurry method is
facile, requires less labor, and the needed equipment is
available in most laboratories. Herein, we observed a 94%
success rate for slurry using the five preferred68 solvents
selected for study. Interestingly, only 4% of the resulting
cocrystals contained coformer as an impurity compared to 28%
of the SDG experiments. The gathering of preliminary
solubility data was crucial to select suitable conditions for
our slurry experiments. Our study encompassed a broad range
of solubilities, both absolutely and relatively, as exemplified by
cocrystal 5, which formed in all five solvents. Cocrystal 5 is a
1:1 cocrystal between glutaric acid and 1,2-bis(4-pyridyl)-
ethane, and the coformers exhibit similar solubility in methanol
(458.0 mg/mL an 426.6 mg/mL, respectively) but a difference
of >500 mg/mL in water and EtOAc (Table 1). On the
contrary, cocrystals for which both coformers exhibit a
solubility of <1 mg/mL were cocrystal 1, benzoic acid, and
trans-1,2-bis(4-pyridyl)ethylene in water.
It is perhaps an unexpected finding of this study that water
proved to be an appropriate solvent for synthesizing cocrystals
with an 80% success rate across slurry and SDG experiments.
Water is not an ideal solvent for solution crystallization as APIs
targeted for cocrystallization tend to exhibit low aqueous
solubility and many cocrystals are metastable at the
stoichiometry of the cocrystal.70 Nevertheless, from an
industry perspective, water is probably the most desirable
solvent for safety, economic, and environmental reasons.68
Further, if the goal of cocrystallization screening is to increase
the aqueous solubility of an API, then water slurry could be
optimal as when cocrystals are produced, it is likely to be in
high yield. Even CBZ, which readily forms a dihydrate, formed
cocrystals in water. Moreover, slurrying is likely to directly
afford thermodynamically stable solid forms,49 a feature
desirable in pharmaceutical dosage forms as it reduces the
risks of phase changes occurring during the later stages of drug
development (e.g., during manufacturing and storage).
This study herein does not address other factors that are
relevant from a practical utility perspective, including
crystallinity, particle size, and bulk purity, each of which can
impact dissolution rate and tabletability.72 For example,
Rahman and co-workers73 compared the dissolution rate of
an acyclovir-succinic acid cocrystal made via either slurrying or
grinding. They reported that the cocrystal formed by slurrying
exhibited a faster dissolution rate compared to the poorly
crystalline product afforded by grinding.
■ CONCLUSIONS
In conclusion, solution crystallization is the traditional method
for preparing cocrystals but can require many trial-and-error
experiments because the solid form obtained is sensitive to the
concentration and solvent used as illustrated by ternary phase
diagrams.26,57,58 Ternary phase diagrams are influenced by the
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relative solubility of the pure coformers; coformers with similar
solubility values are more likely to undergo congruent
dissolution compared to coformers that are of very different
solubility. This was highlighted by Peterson et al., who
reported very different ternary phase diagrams in water versus
methanol for the 1:1 cocrystal of trans-cinnamic acid and
nicotinamide.57 The study herein revealed that both SDG and
slurry methodologies resulted in high success rates: slurry was
successful in 94% of attempts; 78.5% of the SDG attempts
were successful. Several cocrystals that did not form by SDG
were readily afforded via slurry in the same solvent, or vice
versa. We conclude from these results that supersaturation
conditions played a key role in the overall success rate of both
methodologies. We note that SDG and slurry as conducted
herein result in saturation of both coformers. Therefore, our
results are consistent with previous studies, which reported
that increasing coformer concentration resulted in decreasing
the solubility of the targeted cocrystal.26,58
In terms of comparing SDG with slurry, SDG is advanta-
geous because it can produce cocrystals fast and in high yield
with little or no solvent, but purity of products can be an issue
(72% of cocrystals isolated by SDG were pure according to
PXRD). Subsequent purification of cocrystals adds an
additional step that can reduce the yield of a cocrystal or
worse if supersaturation conditions are not maintained during
washing (the least soluble coformer may precipitate).52 The
slurry method, on the other hand, resulted in cocrystal
products that were PXRD pure 96% of the time. On balance,
based upon the library of cocrystals studied herein, we consider
that slurrying, even water slurrying, offers a facile and effective
approach for cocrystal discovery and production. Indeed, that
water proved to be a suitable solvent for both slurrying and
SDG is perhaps the most surprising and relevant aspect of the
results we report herein.
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